A retrospective study analysing effect of low-dose ruxolitinib (daily dose ≤ 10 mg) for the treatment of myelofibrosis
Latest Information Update: 29 Jan 2021
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2021 New trial record
- 01 Jan 2021 Results published in the Annals of Hematology